Kisspeptin-10 vs Orforglipron
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Kisspeptin-10
Kisspeptin-10 is the active fragment of kisspeptin, a hormone that plays a crucial role in initiating puberty and regulating reproductive function. It acts upstream of GnRH in the hypothalamic-pituitary-gonadal axis.
Full details →Orforglipron
Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (which is a peptide requiring special formulation), orforglipron is a small molecule — the first of a new class of oral GLP-1 drugs that can be taken without fasting restrictions. It is in Phase 3 trials for obesity and type 2 diabetes, with an FDA decision expected in 2026. Projected to reach $16 billion in annual sales by 2031.
Full details →Side-by-Side Comparison
| Aspect | Kisspeptin-10 | Orforglipron |
|---|---|---|
| Dose Range | 100 mcg–1 mg | 12 mg–45 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | — |
| Route | subcutaneous | oral |
| Mechanism | Binds to KISS1R receptors in the hypothalamus, stimulating GnRH neurons to release GnRH. This triggers the downstream cascade of LH, FSH, and sex hormone production. | Orforglipron is a small-molecule agonist that binds and activates the GLP-1 receptor through the same signaling cascade as peptide GLP-1 agonists (cAMP elevation, insulin secretion, appetite suppression) but with a fundamentally different molecular structure. Being a non-peptide, it does not require protection from enzymatic degradation (no fatty acid conjugation needed), can be absorbed without special formulation, and has no fasting restrictions for administration. Once-daily oral dosing with a half-life of ~25-65 hours. |
| Typical Dosage | Research protocols vary widely. Studies have used IV boluses of 1-10mcg/kg or subcutaneous administration. Clinical applications still being developed. | Phase 2 trial doses: 12 mg, 24 mg, 36 mg, and 45 mg daily. The 36 mg and 45 mg doses showed greatest efficacy. Phase 3 trials are evaluating doses of 12-60 mg daily. No fasting requirement — can be taken with or without food at any time of day. Final approved dosing not yet established. |
| Administration | IV or subcutaneous injection. Has very short half-life requiring frequent administration or continuous infusion for sustained effects. | Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available. |
| Side Effects | Limited data. May cause flushing, increased heart rate, and changes in libido. Generally well-tolerated in studies. | Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%. |
| Best For |
Key Differences
Unique to Kisspeptin-10:
Unique to Orforglipron:
Key Studies
Kisspeptin-10
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.
European journal of endocrinology, 2026
- Kisspeptin-10 Protects Against TNF-α-Induced Chondrocyte Senescence via the SIRT1/p53/p21 Signaling.
Journal of biochemical and molecular toxicology, 2025
- Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.
Biomolecules, 2025
Orforglipron
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Lancet (London, England), 2026
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Nature medicine, 2026
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
JAMA, 2026
Ready to Learn More?
Looking for trusted sources?